Expression of VHL and HIF-1α and their clinicopathologic significance in benign and malignant lesions of the gallbladder

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 6, 2011, Pages 534-539

  Yang, Zhulin ^a   Yang, Zhi ^a   Xiong, Li ^a   Huang, Shengfu ^a   Liu, Jieqiong ^a   Yang, Leping ^a   Miao, Xiongying ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

gallbladder neoplasm; hypoxia inducible factor 1a; immunohistochemistry; Von Hippel Lindau gene

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PARAFFIN; VON HIPPEL LINDAU PROTEIN;

ADENOCARCINOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHRONIC CHOLECYSTITIS; FEMALE; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CARCINOMA; GALLBLADDER EPITHELIUM; GALLBLADDER TUMOR; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; GALLBLADDER; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; SURVIVAL ANALYSIS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 81755176069     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318212f001     Document Type: Article

References (20)

1. Jones RS. Carcinoma of the gallbladder. Surg Clin North Am. 1990; 70:1419-1428.
2. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171-190.
3. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma: with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
4. Corless CL, Kibel AS, Iliopoulos O, et al. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997;28:459-464. (Pubitemid 27175087)
5. Kivela AJ, Parkkila S, Saarnio J, et al. Expression of von Hippel- Lindau tumor suppressor and tumor-associated carbonic anlydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol. 2005;11:2616-2625. (Pubitemid 40704279)
6. Kaolin WG Jr. The von Hippel-Lindau tumor suppressor protein: an update. Methods Enzymol. 2007;435:371-383.
7. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004. (Pubitemid 46646218)
8. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 2008;15:650-659. (Pubitemid 351405068)
9. He Z, Liu S, Guo M, et al. Expression of fibronectin and HIF-1 alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. Cancer Genet Cytogenet. 2004;152:89-94. (Pubitemid 38953007)
10. Maina EN, Morris MR, Zatyka M, et al. Identification of novel VHL genes and relationship to hypoxic response pathway. Oncogene. 2005;24:4549-4558. (Pubitemid 41032618)
11. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol. 2003;13:83-89. (Pubitemid 36269184)
12. Nyhan MJ, O'Sullivan GC, McKenna SL. Role of the VHL (von Hippel-lindau) gene in renal cancer: a multifunctional tumor suppressor. Biochem Soc Trans. 2008;36:472-478. (Pubitemid 351839358)
13. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2008;8:63-73.
14. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275. (Pubitemid 29246458)
15. Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. Lancet. 2003;361:2059-2067. (Pubitemid 36695052)
16. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90. (Pubitemid 24232386)
17. Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxiainducible factor-1 alpha, histone deacetylase1 and metastasisassociated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1-e9. (Pubitemid 351440946)
18. Giatromanolaki A, Sivridis E, Simopoulos C, et al. Hypoxia inducible factors 1 alpha and 2 alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol. 2006;94:242-247. (Pubitemid 44289989)
19. Wada H, Nagano H, Yamamoto H, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia- induced factor-1 alpha. Liver Int. 2006;26:414-423.
20. Ardyanto TD, Osiki M, Nagahama Y, et al. Down-regulation of cobalt-induced HIF-1 alph expression correlates with cell proliferation and apoptosis in human gastric carcinoma cells. Oncol Rep. 2008;19:339-343. (Pubitemid 351176092)